Table 4.

Incidence of renal end pointsa

End PointPerindopril- Indapamide (No. of Events/Patient [%])PlaceboHR (95% CI)PNNT
Progression of nephropathy
    all renal events1243/5569 (22.3)1500/5571 (26.9)0.79 (0.73 to 0.85)<0.000120
    progression of ≥1 albuminuria stage1179/5436 (21.7)1442/5412 (26.6)0.78 (0.72 to 0.84)<0.000118
    new-onset microalbuminuria1094/3995 (27.4)1317/3991 (33.0)0.79 (0.73 to 0.86)<0.000116
    new-onset macroalbuminuria114/5436 (2.1)163/5412 (3.0)0.69 (0.54 to 0.88)0.002797
        patients with normoalbuminuria25/3995 (0.6)35/3991 (0.9)0.71 (0.42 to 1.18)0.1841NA
        patients with microalbuminuria89/1441 (6.2)128/1421 (9.0)0.69 (0.52 to 0.91)0.007432
    doubling of serum creatinine >200 μmol/L55/5569 (1.0)45/5571 (0.8)1.21 (0.81 to 1.79)0.3483NA
    end-stage kidney diseaseb25/5569 (0.4)21/5571 (0.4)1.18 (0.66 to 2.11)0.5736NA
Regression of nephropathy
        regression of ≥1 albuminuria stage908/1638 (55.4)816/1625 (50.2)1.16 (1.06 to 1.28)0.001719
    regression to normoalbuminuria848/1638 (51.8)745/1625 (45.8)1.15 (1.04 to 1.27)0.005916
        patients with microalbuminuria797/1441 (55.3)698/1421 (49.1)1.15 (1.04 to 1.27)0.006716
        patients with macroalbuminuria51/197 (25.9)47/204 (23.0)1.08 (0.72 to 1.60)0.7146NA
  • a NA, not applicable; NNT, number needed to treat to prevent one event of nephropathy progression or to promote one event of nephropathy regression over 5 yr.

  • b Defined as requirement of renal replacement therapy or renal death.